Federal grants to Abalone Bio, Inc.
Abalone Bio, Inc. in Emeryville, California received $5.8 million in federal grants from fiscal 2021 to 2025, across 6 awards. Its largest program was Diabetes, Digestive, and Kidney Diseases Extramural Research, with $2.3 million. It had no new grant money in fiscal 2025.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$5.8 million
- Awards6
- Awarded in FY 2025$0
- Largest award$2.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 3 | $2.0 million |
| FY 2022 | 3 | $2.4 million |
| FY 2023 | 1 | $999,999 |
| FY 2024 | 1 | $399,230 |
| FY 2025 | 0 | $0 |
Programs that fund Abalone Bio, Inc.
| Program | Awards | Amount |
|---|---|---|
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 2 | $2.3 million |
| Cancer Treatment Research | 1 | $2.0 million |
| Engineering | 1 | $799,997 |
| Drug Use and Addiction Research Programs | 1 | $399,230 |
| Child Health and Human Development Extramural Research | 1 | $292,942 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 5 | $5.0 million |
| National Science Foundation | 1 | $799,997 |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Therapeutic antibodies for treating liver fibrosis - abstract cirrhosis of the liver is among the top ten leading causes of death in the us, with more than 35,000 deaths each year. A major underlying cause of cirrhosis is liver injury associated with liver fibrosis, i.e., scar tissue that blocks the | Diabetes, Digestive, and Kidney Diseases Extramural Research | July 15, 2022 | $2.0 million |
| Therapeutic antibodies for treating chemotherapy induced peripheral neuropathic pain - abstract chemotherapy-induced peripheral neuropathy (CIPN) is an often long-lasting neurological condition that arises frequently in cancer patients who receive broadly used chemotherapies such as taxanes. Cipn ca | Cancer Treatment Research | May 4, 2021 | $2.0 million |
| Sbir phase II: a platform for identifying antibodies that modulate human membrane receptors involved in disease | Engineering | October 6, 2020 | $799,997 |
| A peripherally restricted mor agonist for effective pain management with reduced risks - abstract although opioids are effective in the treatment of moderate to severe pain, they are addictive and have dangerous side-effects, including respiratory depression, constipation, sedation, nausea and dizzi | Drug Use and Addiction Research Programs | March 19, 2024 | $399,230 |
| Therapeutic antibodies for treating inflammatory bowel disease - summary abalone bio will develop antibody (AB) drugs that inhibit intestinal inflammation to treat inflammatory bowel disease (IBD). Ibd comprises chronic, debilitating, idiopathic inflammatory diseases that result in severe dam- age t | Diabetes, Digestive, and Kidney Diseases Extramural Research | April 22, 2021 | $300,241 |
| Antibody agonist for a g protein-coupled receptor as a treatment for pain in endometriosis - abstract endometriosis is a chronic, painful and debilitating gynecological condition associated with vascularized, fibrotic, and innervated peritoneal lesions resembling endometrial glands, estimated to be | Child Health and Human Development Extramural Research | June 10, 2022 | $292,942 |
Questions people ask
How much federal grant money does Abalone Bio, Inc. get?
$5.8 million in 6 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Abalone Bio, Inc. the most?
The Department of Health and Human Services, with $5.0 million in 5 awards. The National Science Foundation follow.
What is Abalone Bio, Inc.'s largest federal grant?
$2.0 million under Diabetes, Digestive, and Kidney Diseases Extramural Research, with its first action in the period on July 15, 2022. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Abalone Bio, Inc.?
Its largest are Diabetes, Digestive, and Kidney Diseases Extramural Research, Cancer Treatment Research and Engineering.
Other grant recipients in Emeryville
- Bioindustrial Manufacturing and Design Ecosystem
- Grid Alternatives
- Engineering Biology Research Consortium
- Eko Health, Inc.
- Resvita Bio Inc
- Cal-Pep
- Topaz Biosciences, Inc.
- City of Emeryville
Largest federal grant recipients in California · Federal grants in California